2hwr: Difference between revisions

From Proteopedia
Jump to navigationJump to search
Newer edit →
OCA (talk | contribs)
Bots, Bureaucrats, journal, Administrators
3,328,572 edits
New page: left|200px<br /> <applet load="2hwr" size="450" color="white" frame="true" align="right" spinBox="true" caption="2hwr, resolution 2.34Å" /> '''Structural basis fo...
 
OCA (talk | contribs)
Bots, Bureaucrats, journal, Administrators
3,328,572 edits
No edit summary
Line 1: Line 1:
[[Image:2hwr.gif|left|200px]]<br />
[[Image:2hwr.jpg|left|200px]]<br /><applet load="2hwr" size="350" color="white" frame="true" align="right" spinBox="true"  
<applet load="2hwr" size="450" color="white" frame="true" align="right" spinBox="true"  
caption="2hwr, resolution 2.34&Aring;" />
caption="2hwr, resolution 2.34&Aring;" />
'''Structural basis for the structure-activity relationships of Peroxisome Proliferator-Activated Receptor agonists'''<br />
'''Structural basis for the structure-activity relationships of Peroxisome Proliferator-Activated Receptor agonists'''<br />
Line 6: Line 5:
==Overview==
==Overview==
Type 2 diabetes has rapidly reached an epidemic proportion becoming a, major threat to global public health. PPAR agonists have emerged as a, leading class of oral antidiabetic drugs. We report a structure biology, analysis of novel indole-based PPAR agonists to explain the, structure-activity relationships and present a critical analysis of, reasons for change in selectivity with change in the orientation of the, same scaffolds. The results would be helpful in designing novel PPAR, agonists.
Type 2 diabetes has rapidly reached an epidemic proportion becoming a, major threat to global public health. PPAR agonists have emerged as a, leading class of oral antidiabetic drugs. We report a structure biology, analysis of novel indole-based PPAR agonists to explain the, structure-activity relationships and present a critical analysis of, reasons for change in selectivity with change in the orientation of the, same scaffolds. The results would be helpful in designing novel PPAR, agonists.
==Disease==
Known diseases associated with this structure: Abdominal body fat distribution, modifier of OMIM:[[http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=601487 601487]], Diabetes mellitus, insulin-resistant, with acanthosis nigricans and hypertension OMIM:[[http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=601487 601487]], Glioblastoma, susceptibility to OMIM:[[http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=601487 601487]], Insulin resistance, severe, digenic OMIM:[[http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=601487 601487]], Lipodystrophy, familial partial OMIM:[[http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=601487 601487]], Obesity, resistance to OMIM:[[http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=601487 601487]], Obesity, severe OMIM:[[http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=601487 601487]]


==About this Structure==
==About this Structure==
2HWR is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with DRD as [http://en.wikipedia.org/wiki/ligand ligand]. Full crystallographic information is available from [http://ispc.weizmann.ac.il/oca-bin/ocashort?id=2HWR OCA].  
2HWR is a [http://en.wikipedia.org/wiki/Single_protein Single protein] structure of sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with <scene name='pdbligand=DRD:'>DRD</scene> as [http://en.wikipedia.org/wiki/ligand ligand]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2HWR OCA].  


==Reference==
==Reference==
Line 27: Line 23:
[[Category: ppar]]
[[Category: ppar]]


''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on Mon Nov 12 22:37:41 2007''
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Wed Jan 23 14:15:32 2008''
Retrieved from "https://proteopedia.org/2hwr"